Diagnostics products developer Autobio Diagnostics plans to invest $29.33m in purchasing 75% stake in Beijing Bio-Top, an in-vitro diagnostics company based in Beijing, China.

Urological medical devices developer MedicaMetrix will be acquired by Cardiff International in a $6m all-stock transaction.

The target company will merge into Cardiff and will operate as its subsidiary.

The acquisition enables Cardiff, a software systems developer, to enter the medical device field.

Sygnis AG intends to acquire Innova Biosciences for a purchase consideration of approximately $10m, which will be paid through $8.79m in cash and will issue up to 3.5 million shares.

The acquirer company expects the acquisition to strengthen its portfolio with a labelling technology lightning link.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“Sygnis AG expects the acquisition to strengthen its portfolio with a labelling technology lightning link. “

Sygnis is a molecular biology company involved in the development of novel products, while Innova Biosciences offers bioconjugation technologies and services.

Luxendo GmbH has been acquired by Bruker Corporation in a move to expand its fluorescence microscopy portfolio.

Luxendo is engaged in developing advanced single plane illumination microscopes (SPIM), while Bruker is a provider of scientific instruments and diagnostic solutions.

In a $2.99m deal, MG Med intends to acquire 17.1% stake in Oxford Cancer Biomarkers.

MG Med is engaged in molecular diagnostics, while Oxford Cancer Biomarkers is a developer of biomarker diagnostic products.